Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
30 December 2015Website:
http://oncocyte.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 20:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
OCX Latest News
IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.
IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure.
IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine . Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study ( NCT05021484 ) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Participants Mike Matson - Needham Jacob Krahenbuhl - Stephens Vidyun Bais - BTIG Operator Thank you for standing by. My name is Tamika and I will be your conference operator today.
OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call Participants Mike Matson - Needham & Co. Operator Welcome to the OncoCyte Q2 2023 Earnings Call. All participants will be in listen-only mode.
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open.
Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).
What type of business is OncoCyte?
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
What sector is OncoCyte in?
OncoCyte is in the Healthcare sector
What industry is OncoCyte in?
OncoCyte is in the Diagnostics & Research industry
What country is OncoCyte from?
OncoCyte is headquartered in United States
When did OncoCyte go public?
OncoCyte initial public offering (IPO) was on 30 December 2015
What is OncoCyte website?
https://oncocyte.com
Is OncoCyte in the S&P 500?
No, OncoCyte is not included in the S&P 500 index
Is OncoCyte in the NASDAQ 100?
No, OncoCyte is not included in the NASDAQ 100 index
Is OncoCyte in the Dow Jones?
No, OncoCyte is not included in the Dow Jones index
When does OncoCyte report earnings?
The next expected earnings date for OncoCyte is 09 August 2024